Turnstone Biologics Files for $86M IPO Amid Financial Difficulties

An initial public offering from Turnstone Biologics may prove a turning point for the struggling biotech company, which is hoping to raise $86 million in a Nasdaq IPO, according to an SEC filing Monday. The announcement is only the eighth biotech IPO this year, and would reportedly be the fifth-largest offering of 2023.